The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | The role of neoadjuvant immunotherapy in MSI-high gastric cancer
Nataliya Uboha, MD, PhD, UW Carbone Cancer Center, Madison, WI, provides some of her highlights from the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium, including data from a trial assessing neoadjuvant immunotherapy in patients with microsatellite instability-high (MSI) gastric adenocarcinoma. The findings highlight MSI-high gastric cancer as a distinct subtype, and build on previous data from the Phase II GERCOR NEONIPIGA study (NCT04006262). This interview took place at the ASCO 2023 GI Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
